Does Rinvoq Work for Rheumatoid Arthritis?
Yes, Rinvoq (upadacitinib) is FDA-approved for moderate to severe rheumatoid arthritis (RA) in adults who have not responded well to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). It reduces signs and symptoms, inhibits joint damage progression, and improves physical function.[1][2]
Clinical trials like SELECT-COMPARE and SELECT-MONOTHERAPY showed Rinvoq 15 mg once daily met primary endpoints. In SELECT-COMPARE, 70% of patients achieved ACR20 response (20% improvement in American College of Rheumatology criteria) at 12 weeks versus 51% on placebo plus methotrexate. Radiographic progression slowed significantly over 26 weeks.[3][4]
How Does Rinvoq Compare to Other RA Treatments?
Rinvoq, a JAK inhibitor, outperforms adalimumab (Humira) plus methotrexate in some head-to-head data: 72% ACR50 response (50% improvement) at week 12 for Rinvoq versus 64% for Humira combo.[3] It matches or exceeds other JAKs like Xeljanz (tofacitinib) in remission rates but has a once-daily oral dosing edge over injectables like Enbrel or Rituxan.[5]
| Treatment | Dosing | ACR20 Response (Week 12) | Key Difference |
|-----------|--------|---------------------------|---------------|
| Rinvoq 15 mg | Oral daily | 71-76%[3] | Faster onset, oral convenience |
| Humira + MTX | Injection weekly | 64%[3] | More infections in combo arms |
| Xeljanz 5 mg BID | Oral twice daily | 65-69%[6] | Similar efficacy, boxed warning overlap |
What Side Effects Do RA Patients Report?
Common issues include upper respiratory infections (14%), nausea (6%), and elevated liver enzymes. Serious risks: infections (herpes zoster, pneumonia), blood clots, heart events, cancer, and gastrointestinal tears—leading to a boxed warning shared by all JAK inhibitors post-ORAL Surveillance trial linking higher MACE/death rates.[2][7] RA patients over 50 with heart risk factors face elevated concerns.
When Did Rinvoq Get Approved for RA and What's the Patent Status?
FDA approved Rinvoq for RA in August 2019, expanding from atopic dermatitis.[1] Patents extend protection: core composition-of-matter patent US 8,420,684 expires December 2029 in the US, with others to 2033+ and potential pediatric extensions. No generics until at least 2030; AbbVie faces Paragraph IV challenges but maintains exclusivity.[8]DrugPatentWatch.com
Who Makes Rinvoq and How Much Does It Cost?
AbbVie manufactures and markets Rinvoq. US list price is about $6,200 monthly for 15 mg tablets before discounts/insurance; patient assistance caps copays at $5 for eligible uninsured.[9]
Sources
[1]: FDA Label - Rinvoq
[2]: RINVOQ.com - RA Indication
[3]: NEJM - SELECT-COMPARE Trial
[4]: Lancet - SELECT-MONOTHERAPY
[5]: Arthritis.org - JAK Inhibitors Comparison
[6]: FDA Label - Xeljanz
[7]: FDA - JAK Safety Update
[8]: DrugPatentWatch - Rinvoq Patents
[9]: AbbVie Patient Assistance